Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for hepatitis b: experimental drug aims to silence the virus

NCT ID NCT06550128

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times

Summary

This study tests an experimental drug called AHB-137 in adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral therapy. The goal is to see if adding AHB-137 can lower hepatitis B virus markers (HBsAg and HBV DNA) to undetectable levels. About 86 participants will receive either AHB-137 or a placebo alongside their usual medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • The First Hospital of Jilin University

    Jilin, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • The third People's Hospital of Zhenjiang

    Zhenjiang, Jiangsu, China

Conditions

Explore the condition pages connected to this study.